A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis.

Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis.

Stanford is now accepting new patients for this trial. Please contact Angela Campbell at 650-721-6188 for more information.


  • drug : Placebo
  • drug : BAF312

Phase: Phase 3


Ages Eligible For Study:

18 Years - 60 Years

Inclusion Criteria

- Prior history of relapsing remitting MS - SPMS defined as progressive increase of disability over at least 6 months - EDSS score of 3.0 to 6.5 - No relapse of corticosteroid treatment within 3 months

External Links

Explore related trials

Contact information

Primary Contact:

Angela Campbell 650-721-6188

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: